Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Frederik Christiaan Berrevoet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3575-5345; OpenAlex author ID A5050447247. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
97
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 6 papers · 2026: 3 papers

Papers 19

  1. Longitudinal assessment of health-related quality of life in patients with borderline and locally advanced pancreatic cancer undergoing neoadjuvant FOLFIRINOX … Last author DOI 10.1007/s00423-026-04121-3↗
  2. Success rate of salvage neoadjuvant chemotherapy for unexpectedly identified locally advanced pancreatic ductal adenocarcinoma during surgical exploration. Last author DOI 10.1016/j.hpb.2025.10.003↗
  3. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  6. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  7. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  8. Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicente… Last author DOI 10.1186/s12893-025-02938-1↗
  9. Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience. Last author DOI 10.3390/curroncol32100574↗
  10. Long-term complete remission of two patients with synchronous liver metastasis from pancreatic cancer and underlying BRCA-2 mutation. Co-author DOI 10.51821/87.4.11787↗
  11. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities? Last author DOI 10.1186/s12893-023-02200-6↗
  12. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  13. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. First author DOI 10.1016/j.esmoop.2022.100386↗
  14. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  15. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  16. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  17. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  18. Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31829a80b7↗
  19. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Filip Gryspeerdt · 4 shared papers, 2023–2026 · strength 0.97
  2. Karen Paula Geboes · 5 shared papers, 2013–2026 · strength 0.96
  3. L.F. Abreu de Carvalho · 4 shared papers, 2023–2026 · strength 0.96
  4. Geert Roeyen · 4 shared papers, 2018–2025 · strength 0.51
  5. Marc G. Besselink · 5 shared papers, 2018–2025 · strength 0.41
  6. Roberto Salvia · 5 shared papers, 2018–2025 · strength 0.41
  7. Mickaël Lesurtel · 5 shared papers, 2011–2025 · strength 0.35
  8. Marco Del Chiaro · 4 shared papers, 2018–2025 · strength 0.33
  9. Jorg H. Kleeff · 4 shared papers, 2018–2025 · strength 0.33
  10. Giuseppe Fusai · 4 shared papers, 2018–2025 · strength 0.33
  11. Knut Jørgen Labori · 4 shared papers, 2018–2025 · strength 0.33
  12. Alberto Balduzzi · 3 shared papers, 2020–2025 · strength 0.31
  13. Tobias Keck · 3 shared papers, 2020–2025 · strength 0.31
  14. Adnan A. Alseidi · 3 shared papers, 2020–2025 · strength 0.31
  15. Thilo Hackert · 3 shared papers, 2020–2025 · strength 0.31
  16. Giovanni Butturini · 3 shared papers, 2020–2025 · strength 0.31
  17. Bas Groot Koerkamp · 3 shared papers, 2020–2025 · strength 0.31
  18. António Sá Cunha · 3 shared papers, 2020–2025 · strength 0.31
  19. Massimo Falconi · 3 shared papers, 2020–2025 · strength 0.31
  20. Bart Hendrikx · 1 shared paper, 2025 · strength 0.25
  21. L Crapé · 1 shared paper, 2024 · strength 0.23
  22. S. Ribeiro · 1 shared paper, 2024 · strength 0.23
  23. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  24. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  25. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.